Faculty Profiles - TAKEICHI Takuya

The use of certolizumab pegol to successfully treat generalized pustular psoriasis combined with psoriatic uveitis Reviewed International journal

Kazuki Yatsuzuka, Takuya Matsumoto, Yuri Sakane, Ryo Fukaura, Takuya Takeichi, Masashi Akiyama, Masamoto Murakami

The Journal of Dermatology Vol. 50 ( 6 ) page： E175 - E176 2023.6

Successful combination therapy of bimekizumab and granulocyte monocyte adsorption apheresis for generalized pustular psoriasis complicated with microscopic polyangiitis. Reviewed International journal

Rie Shukuin, Haruka Koizumi, Aoi Ebata, Satoko Imai, Yuta Yamashita, Mariko Ogawa-Momohara, Takuya Takeichi, Yoshinao Muro, Norito Takami, Masashi Akiyama

The Journal of dermatology Vol. 50 ( 6 ) page： E181 - E182 2023.6

Ichthyotic skin lesions of Conradi-Hünermann-Happle syndrome successfully treated with dupilumab. Reviewed International journal

Ryo Fukaura, Takuya Takeichi, Aoi Ebata, Chiaki Murase, Yoshinao Muro, Masashi Akiyama

Journal of the European Academy of Dermatology and Venereology : JEADV Vol. 37 ( 6 ) page： E732 - E734 2023.6

COVID-19 infection- and vaccination-related exacerbation of Darier's disease in a single patient. Reviewed International journal

Ryo Fukaura, Takuya Takeichi, Aoi Ebata, Yoshinao Muro, Masashi Akiyama

The Journal of dermatology Vol. 50 ( 6 ) page： 833 - 836 2023.6

Language：English Publishing type：Research paper (scientific journal)

Darier's disease (DD) is a rare autosomal dominantly inherited disorder. DD patients usually present with widespread keratotic eruptions with itching in the seborrheic regions that are exacerbated by various factors, including heat, sweat, and physical trauma. The SARS-CoV-2 (COVID-19) pandemic has stirred confusion among the medical community, including dermatologists, as this infection has been implicated in various skin conditions. Only a handful of reports have documented DD associated with COVID-19. Here, we report a 30-year-old male with Darier's disease whose symptoms were exacerbated following both COVID-19 vaccination and COVID-19 infection. The patient had noticed slight eruptions 7 years prior, but was not particularly concerned. After COVID-19 vaccination and infection, he had erythematous maculopapular lesions in large areas of the trunk and extremities. The previously reported pathogenic variant c.2255_2257del (p.(Ile752_Tyr753delinsAsn)) in ATP2A2 was detected in the present patient. Oral etretinate greatly improved his DD manifestations. As far as we know, the present patient is the first genetically confirmed DD case who showed both COVID-19 infection- and vaccination-related DD exacerbations independently. We think that the further accumulation of DD cases exacerbated by COVID-19 infection/vaccination is needed to clarify the mechanisms of DD aggravation.

DOI： 10.1111/1346-8138.16725

Current understanding of the phenotypic spectrum of patients with NLRP1 variants. Reviewed International journal

Takuya Takeichi, Masashi Akiyama

The British journal of dermatology Vol. 188 ( 2 ) page： 160 - + 2023.2

Development of pemphigus vegetans and exacerbation of pemphigus foliaceus after secukinumab loading in a patient with complicated generalized pustular psoriasis and pyoderma gangrenosum. Reviewed International journal

Lisa Minai, Takuya Takeichi, Youichi Ogawa, Akiko Honobe-Tabuchi, Takashi Okamoto, Hiroshi Mitsui, Shinji Shimada, Masashi Akiyama, Tatsuyoshi Kawamura

The Journal of dermatology Vol. 50 ( 2 ) page： 245 - 249 2023.2

Language：English Publishing type：Research paper (scientific journal)

In dermatology, biologics that block signaling pathways of TNF-α, IL-4/IL13, IL-17s, and IL-23 are widely used for the treatment of several inflammatory skin diseases, such as atopic dermatitis and psoriasis. They have shown excellent efficacy with an acceptable safety profile. However, these biologics targeting pathogenic cytokines and their receptors could modulate immunological balance, leading to the development of other inflammatory or autoimmune skin diseases in some cases. In this study, we present a patient who suffered pemphigus vegetans and showed an exacerbation of pemphigus foliaceus after secukinumab loading for the treatment of complicated generalized pustular psoriasis and pyoderma gangrenosum.

DOI： 10.1111/1346-8138.16563

Prominent dermal accumulation of Russell bodies underlying pseudocarcinomatous hyperplasia with fungal infection. Reviewed

Exploring biomarkers to predict clinical improvement of atopic dermatitis in patients treated with dupilumab (B-PAD study). Reviewed International journal

Takeshi Nakahara, Kenji Izuhara, Daisuke Onozuka, Hidehisa Saeki, Satoshi Nunomura, Motoi Takenaka, Mai Matsumoto, Yoko Kataoka, Rai Fujimoto, Sakae Kaneko, Eishin Morita, Akio Tanaka, Michihiro Hide, Tatsuro Okano, Tomomitsu Miyagaki, Natsuko Aoki, Kimiko Nakajima, Susumu Ichiyama, Makiko Kido-Nakahara, Kyoko Tonomura, Yukinobu Nakagawa, Risa Tamagawa-Mineoka, Koji Masuda, Takuya Takeichi, Masashi Akiyama, Yozo Ishiuji, Michie Katsuta, Yuki Kinoshita, Chiharu Tateishi, Aya Yamamoto, Akimichi Morita, Haruna Matsuda-Hirose, Yutaka Hatano, Hiroshi Kawasaki, Keiji Tanese, Mamitaro Ohtsuki, Koji Kamiya, Yudai Kabata, Riichiro Abe, Hiroshi Mitsui, Tatsuyoshi Kawamura, Gaku Tsuji, Norito Katoh, Masutaka Furue

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology Vol. 53 ( 2 ) page： 233 - 238 2023.2

Whole-exome sequencing reveals a retinitis pigmentosa-causative PRPH2 variant as a secondary finding in a patient with pseudoxanthoma elasticum. International journal

Akira Miyazaki, Takuya Takeichi, Kana Tanahashi, Tomoki Taki, Yosuke Taki, Yoshinao Muro, Masashi Akiyama

The Journal of dermatology Vol. 50 ( 2 ) page： e85 - e86 2023.2

Tatsuhiro Noda, Norika Akashi, Maiko Shimomura, Haruka Koizumi, Miyuki Mizuta, Kosei Nakajima, Takuya Takeichi, Teruyuki Mitsuma, Masashi Akiyama

Nagoya journal of medical science Vol. 85 ( 1 ) page： 123 - 126 2023.2

Language：English

Blockade of the secretion of immunoglobulins leads to their accumulation in plasma cells, resulting in condensed immunoglobulins in the rough endoplasmic reticulum of plasma cells, termed Russell bodies. They are sometimes found in lymphoplasmacellular inflammation of the intestinal mucosa and in lymphoid cell malignancies, but only very rarely in skin diseases. Here, we report an 86-year-old female who presented with a lesion with the prominent accumulation of Russell bodies underlying pseudocarcinomatous hyperplasia with fungal infection in the face. Immunohistochemical staining showed the cells containing Russell bodies to be positive for CD138 and the Russell bodies to be positive for immunoglobulin κ and λ light chains. The present case suggests that when inflammatory cell infiltration with abundant round intracellular eosinophilic materials is observed in the dermis, the dermal accumulation of Russell bodies should be considered in cases with reactive pseudocarcinomatous hyperplasia with fungal infection.

DOI： 10.18999/nagjms.85.1.123

A case of juvenile amyopathic dermatomyositis with anti-transcription intermediary factor 1-α antibody showing negative anti-TIF1-γ ELISA results: Comment on "Case of pembrolizumab-induced dermatomyositis with anti-transcription intermediary factor 1-γ antibody". Reviewed International journal

Haruka Koizumi, Yoshinao Muro, Satoko Imai, Yuta Yamashita, Mariko Ogawa-Momohara, Takuya Takeichi, Megumi Murakami, Teruyuki Mitsuma, Masashi Akiyama

The Journal of dermatology Vol. 50 ( 1 ) page： E39 - E40 2023.1

Novel homozygous missense mutation c.1654G>T in the ALOX12B gene causing congenital ichthyosiform erythroderma. Reviewed International journal

Kotoe Mae, Yoshio Kawakami, Ai Kajita, Takuya Takeichi, Tatsuhiro Noda, Yoji Hirai, Masashi Akiyama, Shin Morizane

The Journal of dermatology Vol. 50 ( 1 ) page： E37 - E38 2023.1

Comment on: Disease evolution in a long-term follow-up of 104 undifferentiated connective tissue disease patients. Reviewed International journal

Yuta Yamashita, Yoshinao Muro, Haruka Koizumi, Mariko Ogawa-Momohara, Takuya Takeichi, Masashi Akiyama

Clinical and experimental rheumatology Vol. 41 ( 1 ) page： 195 - 196 2023.1

Occurrence of cholangiocarcinoma, three years after negative seroconversion of anti-TIF1γ antibody, in a dermatomyositis patient. Reviewed International journal

Ken Horisaki, Yoshinao Muro, Mariko Ogawa-Momohara, Yuta Yamashita, Haruka Koizumi, Takuya Takeichi, Masashi Akiyama

European journal of dermatology : EJD Vol. 33 ( 1 ) page： 48 - 49 2023.1

Comment on: Disease evolution in a long-term follow-up of 104 undifferentiated connective tissue disease patients Reviewed International journal

Yamashita Y., Muro Y., Koizumi H., Ogawa-Momohara M., Takeichi T., Akiyama M.

CLINICAL AND EXPERIMENTAL RHEUMATOLOGY Vol. 41 ( 1 ) page： 195 - 196 2023.1

Appropriate immunoassay systems are needed to evaluate various anticentromere antibodies as biomarkers for disease progression in systemic sclerosis. Reviewed International journal

Yoshinao Muro, Yuta Yamashita, Haruka Koizumi, Mariko Ogawa-Momohara, Takuya Takeichi, Masashi Akiyama

Journal of immunological methods Vol. 512 page： 113400 - 113400 2023.1

Two novel anti-aminoacyl tRNA synthetase antibodies: Autoantibodies against cysteinyl-tRNA synthetase and valyl-tRNA synthetase. Reviewed International journal

Yoshinao Muro, Yuta Yamashita, Haruka Koizumi, Mariko Ogawa-Momohara, Takuya Takeichi, Teruyuki Mitsuma, Masashi Akiyama

Autoimmunity reviews Vol. 21 ( 12 ) page： 103204 - 103204 2022.12

Language：English

Anti-aminoacyl-tRNA synthetase (anti-ARS) antibodies are useful for identifying a clinical subset of patients with inflammatory myopathies. Since the myositis of anti-ARS-positive patients is characterized by a unique set of non-myopathic manifestations, including interstitial lung disease, mechanic's hands, and arthralgia, the patients are classified as having anti-synthetase syndrome. Autoantibodies have been identified to eight kinds of ARSs. Of the other 12 ARSs, eight are components of the "OJ" multi-synthetase complex. Autoantibodies to the four remaining ARSs (CysARS, ValARS, SerARS, and TrpARS) have not been reported to be present in patients with inflammatory myopathies. In this study, we first screened samples from more than 300 Japanese patients majorly consisting of those with dermatomyositis (DM) by our established in-house ELISA to find autoantibodies against the four ARSs described above. Since sera from two DM patients specifically reacted to CysARS or ValARS, we determined their reactivities by immunoprecipitation (IP) with the corresponding recombinant proteins and IP-Western blotting with cellular extract. One patient had several features found in anti-synthetase syndrome, but the other did not. The clinical differences among the various anti-ARS antibodies should be explored in a future work.

DOI： 10.1016/j.autrev.2022.103204